AEON Biopharma, Inc.

AEON Biopharma, Inc. (NYSE American: AEON) is a clinical-stage biopharmaceutical company that entered the public markets through its merger with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra Sponsor, LLC that priced its IPO in 2021. The de-SPAC transaction closed in 2023, listing AEON within the healthcare and life sciences sector with a focus on botulinum toxin-based therapeutic candidates. The company filed an 8-K current report with the SEC on May 14, 2026, continuing its post-merger disclosure cadence. For AEON's complete filing history, deal timeline, and comparable SPAC transaction analytics, sign up for full data access on SpacDesk.